NexGelNXGL
NXGL
About: NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
Employees: 19
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
7% more funds holding
Funds holding: 15 [Q4 2024] → 16 (+1) [Q1 2025]
2.79% more ownership
Funds ownership: 6.85% [Q4 2024] → 9.65% (+2.79%) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
6% less capital invested
Capital invested by funds: $2.08M [Q4 2024] → $1.95M (-$123K) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for NXGL.
Financial journalist opinion
Neutral
Seeking Alpha
1 month ago
NEXGEL, Inc. (NXGL) Q1 2025 Earnings Call Transcript
NEXGEL, Inc. (NASDAQ:NXGL ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Valter Pinto - Managing Director of KCSA Strategic Communications Adam Levy - Chief Executive Officer Joe McGuire - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Eric Ramos - Titan Capital Management Operator Good afternoon. I will be your conference operator today.
Neutral
GlobeNewsWire
1 month ago
NEXGEL to Report First Quarter 2025 Financial Results on May 13th
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa.
Neutral
Seeking Alpha
2 months ago
NEXGEL, Inc. (NXGL) Q4 2024 Earnings Call Transcript
NEXGEL, Inc. (NASDAQ:NXGL ) Q4 2024 Earnings Conference Call March 24, 2025 4:30 PM ET Company Participants Valter Pinto - Managing Director of KCSA Strategic Communications Adam Levy - Chief Executive Officer Joe McGuire - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Good afternoon. I will be your conference operator today.
Neutral
GlobeNewsWire
2 months ago
NEXGEL Reports Record Fourth Quarter and Full Year 2024 Financial Results
Fourth quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior year
Neutral
GlobeNewsWire
2 months ago
NEXGEL to Report Fourth Quarter and Full Year 2024 Financial Results on March 24th
Management will host a conference call at 4:30 p.m. ET on the same day LANGHORNE, Pa.
Neutral
GlobeNewsWire
4 months ago
NEXGEL to Participate in Webull Consumer Virtual Webinar on February 18, 2025
LANGHORNE, Pa., Feb. 13, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will present at the Webull Consumer Virtual Webinar on February 18, 2025.
Neutral
GlobeNewsWire
5 months ago
NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer
LANGHORNE, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Joseph F. McGuire as Chief Financial Officer, effective January 1, 2025. Adam E. Drapczuk III, current Chief Financial Officer, will remain with the Company as a consultant.
Neutral
Seeking Alpha
7 months ago
NEXGEL, Inc. (NXGL) Q3 2024 Earnings Call Transcript
NEXGEL, Inc. (NASDAQ:NXGL ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Maria Honeycutt - Account Director of KCSA Strategic Communications Adam Levy - Chief Executive Officer Adam Drapczuk - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Michael Gustitus - One Pride George Marema - Pareto Adventures Operator Good afternoon, ladies and gentlemen. Welcome to NEXGEL's Third Quarter 2024 Earnings Conference Call.
Neutral
GlobeNewsWire
7 months ago
NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially
Quarterly revenue growth driven by a sequential increase of 99% in branded consumer products and 103% in contract manufacturing
Neutral
GlobeNewsWire
7 months ago
NEXGEL Announces $2,000,000 Registered Direct Offering
LANGHORNE, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 727,272 of its shares of common stock and the issuance of warrants to purchase up to an aggregate of 363,636 shares of common stock for a combined offering purchase price of $2.75 per share of common stock in a registered direct offering. The warrants will have an exercise price of $4.25 per share and be exercisable immediately upon issuance and have a term of five years from the date of issuance.
Charts implemented using Lightweight Charts™